TSC22D4 and Hypoglycemia: Our results thus far demonstrated that hepatic TSC22D4 inhibition (a) improves systemic insulin sensitivity and glucose tolerance without causing episodes of hypoglycaemia under healthy conditions (Fig. 2a) and (b) that TSC22D4 also regulates insulin sensitivity under conditions of (high-fat diet induced) metabolic dysfunction (Fig. 2i).